Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Clinical trial NCT01805271 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01805271
Sponsor: UNICANCER
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Primary Non-metastatic Breast Cancer Who Remain Disease-free

Start date: 2013-03-01
Primary completion: 2020-06-01
Enrollment: 1278

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.